New Alzheimer Disease Study Findings Recently Were Reported by a Researcher at Imperial College London (New proteomic signatures in Alzheimer Disease identification and Mild Cognitive Impairment Classification).

A recent study conducted at Imperial College London focused on identifying new proteomic signatures in Alzheimer's Disease and classifying Mild Cognitive Impairment. The research utilized plasma proteomics to assess AD risk and disease characterization, achieving high accuracy in distinguishing AD from CN and classifying MCI stable and decliners. The study highlighted the potential of plasma proteomic biomarkers in Alzheimer's research and emphasized the reliability of these biomarkers across different platforms. [Extracted from the article]